A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of LEAC-102 in Combination With FOLFOX + Bevacizumab/Cetuximab in Subjects With Advanced Colorectal Cancer
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 30 Apr 2018
At a glance
- Drugs LEAC 102 (Primary) ; Bevacizumab; Cetuximab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Taiwan Leader Biotech Corp
- 23 Apr 2018 Planned End Date changed from 1 Feb 2019 to 1 Feb 2022.
- 23 Apr 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2022.
- 23 Apr 2018 Planned initiation date changed from 1 Jun 2017 to 1 Jun 2020.